RxDoctor Payments DataLook up a doctor →

John Mulvey, MD

Family Medicine · Elkton, MDNPI 1902863509

Payments from drug & device makers

$11,716in general payments, 2019–2025

Across 624 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$889
  • Boehringer Ingelheim$863
  • GSK$856
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$11,676100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,716 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$153,202
Medicare patients
314
Services billed
2,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$62,584
FarxigaDapagliflozin Propanediol64$53,995
EliquisApixaban42$51,240
RybelsusSemaglutide28$38,398
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,851
Xultophy 100-3.6Insulin Degludec/Liraglutide13$27,935
XareltoRivaroxaban27$22,605
OzempicSemaglutide14$22,411
Tresiba Flextouch U-200Insulin Degludec17$20,293
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$18,487
Praluent PenAlirocumab13$12,494
Novolog FlexpenInsulin Aspart18$7,536
Combivent RespimatIpratropium/Albuterol Sulfate12$5,940
QuviviqDaridorexant Hcl11$5,267
Rosuvastatin Calcium182$4,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Xultophy 100-3.6, Ozempic$1,189$88,74455 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,257$72,48289 claims
Boehringer IngelheimJardiance, Combivent Respimat$863$68,52462 claims
PfizerEliquis$821$51,24042 claims
GSKTrelegy Ellipta$856$28,85138 claims
Johnson & JohnsonXarelto$74$22,60527 claims
Idorsia Pharmaceuticals US IncQuviviq$93$5,26711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →